Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva
08 janv. 2024 02h00 HE
|
Essential Pharma
Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva Colobreathe® is an inhaled antibiotic for the management of chronic Pseudomonas aeruginosa infections in...